Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

July 2022; 9 (4) EditorialOpen Access

Programmed Cell Death Protein 1–Positive CD8+ T Cells in Multiple Sclerosis

Exhausted Fighters or Peacekeepers

View ORCID ProfileJoost Smolders, View ORCID ProfileJörg Hamann
First published April 22, 2022, DOI: https://doi.org/10.1212/NXI.0000000000001173
Joost Smolders
From the MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam; Neuroimmunology Research Group (J.S., J.H.), Netherlands Institute for Neuroscience, Amsterdam; andDepartment of Experimental Immunology (J.H.), Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joost Smolders
Jörg Hamann
From the MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam; Neuroimmunology Research Group (J.S., J.H.), Netherlands Institute for Neuroscience, Amsterdam; andDepartment of Experimental Immunology (J.H.), Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, the Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jörg Hamann
  • For correspondence: j.hamann@amsterdamumc.nl
Full PDF
Citation
Programmed Cell Death Protein 1–Positive CD8+ T Cells in Multiple Sclerosis
Exhausted Fighters or Peacekeepers
Joost Smolders, Jörg Hamann
Neurol Neuroimmunol Neuroinflamm Jul 2022, 9 (4) e1173; DOI: 10.1212/NXI.0000000000001173

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
284

Share

  • Article
  • Info & Disclosures
Loading

Programmed cell death protein 1 (PD-1, CD279) is a pleiotropic inhibitory receptor expressed, among others, by several subsets of CD8+ T cells. It not only inhibits T-cell receptor signaling but also suppresses expression of the costimulatory molecule CD28.1 PD-1 was initially described as an apoptosis-associated gene2 but has since been attributed multiple functions. It is readily upregulated after T-cell receptor triggering on naive CD8+ T cells, resulting in a controlled expression of granzyme B during acute T-cell responses.3 In chronic infections and malignancies, exhausted CD8+ T cells prominently express PD-1.4 Not surprisingly, the presence of PD-1 is associated with memory-type CD8+ T cells and figures prominently in the signature of tissue-resident memory T cells.5 In recent years, antibodies against PD-1 and its ligands, PD-L1/L2, have become an important therapy for people having malignancies.4 The role and therapeutic potential of PD-1 in chronically activated inflammatory responses, such as multiple sclerosis (MS), is so far less clear.

In this issue of Neurology® Neuroimmunology & Neuroinflammation, Koto et al.6 investigated the association of CD8+ T cells positive for PD-1 with the disease course of MS and provide a further transcriptional characterization of these cells. They show a reduced presence of PD-1+ CD8+ T cells in the circulation of people with MS, which was recovered by interferon beta (IFN-β) therapy. An induction of PD-1 on CD8+ T cells by IFN-β was shown in an anti–CD3/CD28-stimulated peripheral blood mononuclear cell (PBMC) culture. The latter observation is in accordance with the potentiating role of type 1 interferons in CD8+ T-cell memory formation.7

A relevant question is what the reduced frequency of circulating PD-1+ CD8+ T cells in people with MS means. A relative lack of effector memory (EM) and effector memory re-expressing CD45RA CD8+ T cells in people with MS has been reported.8 The lower abundance of PD-1+ cells could reflect a distinct distribution and/or defective formation of memory T cells, as has been hypothesized to underlie the defective control of Epstein-Barr virus (EBV) by CD8+ T cells in MS.8 Vice versa, a higher expression of PD-1 by CD8+CD57+ T cells has been described as phenotypic characteristic of CD8+ T cells defective in the control of EBV in stable MS.9 Because IFN-β suppresses VLA-4 expression on lymphocytes,10 PD-1+ CD8+ T cells could migrate toward the CNS and therefore be reduced in the circulation. Indeed, CD8+ PD-1+ T cells make up a major part of T cells observed in MS lesions11 as well as in clusters of CSF CD8+ T cells associated with (premorbid) MS.12 Accordingly, Koto et al.6 show a higher expression of PD-1 on CSF CD8+ T cells in MS compared with PBMC.

Regardless of their frequency, the functional interpretation of PD-1+ CD8+ T cells in MS remains intriguing. The high expression of PD-1 on CSF CD8+ T cells could reflect cellular activation because these cells are also CD69+.13 Koto et al.6 show that circulating PD-1+ T cells in IFN-β–treated individuals highly expressed IL-10, whereas expression of proinflammatory cytokines or lytic mediators was not distinct from circulating PD-1− cells. In CD4+ T cells and B cells, IL-10 expression has been mostly associated with anti-inflammation, which could be beneficial for the course of MS.14 Anti-inflammatory IL-10+ CD8+ T cells have been identified in the experimental autoimmune encephalomyelitis mouse model of neuroinflammation.15 Alternatively, high IL-10 expression is a hallmark of exhausted CD8+ T cells. However, exhausted CD8+ T cells also show low expression of proinflammatory cytokines and lytic mediators, which was not found by Koto et al.6 The increased expression of inhibitory receptors (also CTLA-4 and TIGIT) is consistent with an exhausted phenotype, as is the high expression of the transcription factor c-Maf. c-Maf has been identified as key regulator of CD8+ T-cell exhaustion in the context of melanoma-derived T cells.16 Accordingly, c-Maf has previously been identified to induce coinhibitory receptor expression in CD4+ and CD8+ T cells17 and to promote IL-10 and suppress IL-2 production in CD4+ T cells.18

One explanation for the variation in phenotypic and functional characteristics could be the fact that the PD-1+ CD8+ T cells likely make up a heterogeneous polyclonal population with diverse differentiation, activation, and exhaustion states. Techniques allowing clustering of subsets within such populations, like single-cell RNA sequencing, could provide more insights in the functional interpretation of PD-1 expression. Intriguingly, gene sets identified by Koto et al. to be enriched in circulating PD-1+ CD8+ T cells, such as chemokine receptors (high CXCR6 and CCR5 and low CCR7) and lytic mediators (high granzyme K) show a phenotypic similarity with cells isolated from MS and non-MS brain tissue.11,19 This observation suggests this CD8+ T-cell fraction to be enriched for precursors of cells, which home into the brain parenchyma in MS.

On the whole, Koto et al. draw the spotlight on the role of CD8+ T cells in MS and show that a distinct profile of inhibitory receptors and transcriptional regulators characterizes this compartment in MS. The fact that patients with the largest accumulation of these cells in the CSF benefit most from steroid treatment supports the idea that PD-1+ CD8+ T cells play an important role in the inflammatory response in early MS.6 The work by Koto et al. provides a framework to further study these cells in association with CNS surveillance, disease activity, and treatment responses in MS.

Study Funding

No targeted funding reported.

Disclosure

J. Smolders received lecture and/or consultancy fee from Biogen, Merck, Novartis, and Sanofi-Genzyme and financial research support from Biogen. J. Hamann received financial research support from Biogen. Go to Neurology.org/NN for full disclosures.

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by Neurology: Neuroimmunology & Neuroinflammation.

  • See page e1166

  • Received March 6, 2022.
  • Accepted in final form March 25, 2022.
  • Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Hui E,
    2. Cheung J,
    3. Zhu J, et al
    . T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-1433.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Ishida Y,
    2. Agata Y,
    3. Shibahara K,
    4. Honjo T
    . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-3895.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ahn E,
    2. Araki K,
    3. Hashimoto M, et al
    . Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci USA. 2018;115(18):4749-4754.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Hashimoto M,
    2. Kamphorst AO,
    3. Im SJ, et al
    . CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301-318.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kumar BV,
    2. Ma W,
    3. Miron M, et al
    . Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 2017;20(12):2921-2934.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Koto S,
    2. Chihara N,
    3. Akatani R, et al
    . Transcription factor c-Maf dictates immunoregulation of programmed cell death-1 expressed CD8+ T cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1166.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Kolumam GA,
    2. Thomas S,
    3. Thompson LJ,
    4. Sprent J,
    5. Murali-Krishna K
    . Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637-650.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Pender MP,
    2. Csurhes PA,
    3. Pfluger CMm,
    4. Burrows SR
    . Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis. Mult Scler. 2014;20(14):1825-1832.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Cencioni MT,
    2. Magliozzi R,
    3. Nicholas R, et al
    . Programmed death 1 is highly expressed on CD8+ CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. Immunology. 2017;152(4):660-676.
    OpenUrlCrossRef
  10. 10.↵
    1. Calabresi PA,
    2. Pelfrey CM,
    3. Tranquill LR,
    4. Maloni H,
    5. McFarland HF
    . VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology. 1997;49(4):1111-1116.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Fransen NL,
    2. Hsiao CC,
    3. van der Poel M, et al
    . Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. Brain. 2020;143(6):1714-1730.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Beltrán E,
    2. Gerdes LA,
    3. Hansen J, et al
    . Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. J Clin Invest. 2019;129(11):4758-4768.
    OpenUrlCrossRef
  13. 13.↵
    1. Kivisäkk P,
    2. Mahad DJ,
    3. Callahan MK, et al
    . Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA. 2003;100(14):8389-8394.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Rojas OL,
    2. Pröbstel AK,
    3. Porfilio EA, et al
    . Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10. Cell. 2019;176(3):610-624.
    OpenUrlPubMed
  15. 15.↵
    1. Brate AA,
    2. Boyden AW,
    3. Jensen IJ,
    4. Badovinac VP,
    5. Karandikar NJ
    . A functionally distinct CXCR3+/IFN-γ+/IL-10+ subset defines disease-suppressive myelin-specific CD8 T cells. J Immunol. 2021;206(6):1151-1160.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Giordano M,
    2. Henin C,
    3. Maurizio J, et al
    . Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 2015;34(15):2042-2058.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Chihara N,
    2. Madi A,
    3. Kondo T, et al
    . Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018;558(7710):454-459.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Gabryšová L,
    2. Alvarez-Martinez M,
    3. Luisier R, et al
    . c-Maf controls immune responses by regulating disease-specific gene networks and repressing IL-2 in CD4+ T cells. Nat Immunol. 2018;19(5):497-507.
    OpenUrlCrossRef
  19. 19.↵
    1. Smolders J,
    2. Heutinck KM,
    3. Fransen NL, et al
    . Tissue-resident memory T cells populate the human brain. Nat Commun. 2018;9(1):4593.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study Funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • Transcription Factor c-Maf Promotes Immunoregulation of Programmed Cell Death 1–Expressed CD8+ T Cells in Multiple Sclerosis

Topics Discussed

  • All Immunology
  • Multiple sclerosis

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise